Product analysis
Lithium Aspartate 5 mg is aimed at mood support, but benefits from prescription lithium cannot be assumed for this low-dose supplement.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality80
Lithium aspartate has a clearly identified, reasonably favorable form comparison. That does not establish that the low-dose serving improves mood.
Ingredient Transparency100
The lithium amount and form are clearly stated. That makes the serving easy to compare with other lithium supplements.
Value For Money80
The serving price offers favorable value for lithium aspartate. A low price does not establish a mood benefit.
Customer Satisfaction82
Customer feedback is very positive across a substantial number of ratings. That indicates broad satisfaction without confirming mood improvement.
Product Focus82
The single-ingredient formula has a clear mood-focused purpose. Mood benefits at this supplement amount remain unestablished because prescription lithium findings do not transfer to it.
- Format
Capsule - Container
- 100 VegCap(s)
- Per serving
- $0.11
- Customer rating
- 4.7 · 1,347 ratings
Goals
Lithium has clinical mood-treatment evidence at prescription exposures, but that evidence cannot be transferred to this 5 mg supplement serving. The supplied information does not establish mood improvement from trace lithium or lithium aspartate. Recognition of the amount and preparation in the saved comparison does not resolve that difference.
How this product is rated for Mood Support
Ingredient fit100
Goal fit
Dose adequacy
Pathways56
Depth
Breadth
Evidence82
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Lithium (Lithium Aspartate) | 5 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability80
Lithium Compound Optimization
Dose, Safety & Label Transparency100
Elemental Disclosure Precision
Dosage Appropriateness
Value80
Cost Per Serving Efficiency
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
- GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
- A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
- A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.